nAMD Archives - Insight

The approval is based on the 48-week results of PULSAR and PHOTON trials.

The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens ...

The American Medical Association’s United States Adopted Names (USAN) Council, with the WHO, approved the name.

Combination drug therapy demonstrates potential to treat AMD subtype

by rhiannon bowman

February 22, 2022

Data from patients with a subtype of AMD enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with ...

Schematic summarising the research. Fluid was collected from patients with nAMD receiving anti-VEGF therapy. Analyses on the proteins were performed to identify biomarkers that may help predict those who can be safely weaned off treatment within one year. Credit: Isabella Sodhi and Adriana Sodhi.

Study: Third of nAMD patients safely stopped eye injections

by Myles Hume

January 25, 2022

A new study has shown up to a third of neovascular age-related macular degeneration (nAMD) patients may safely be ...

Artificial intelligence: eyecare’s friend of foe?

by Myles Hume

June 11, 2021

Eyetelligence is a new Australian-developed AI system helping clinicians screen for three types of eye disease. PROFESSOR MING HE – ...

MDFA patron Ita Buttrose at the National Press Club in Canberra.

Annual out-of-pocket eye injection costs to double to $3,900 under rebate cut – modelling

by Myles Hume

May 10, 2021

Prominent Australian Ms Ita Buttrose has used a National Press Club address to reveal alarming new data showing that 47,000 ...

Novartis secures PBS recommendation for Beovu

by Myles Hume

April 27, 2021

An independent expert panel has recommended Novartis' treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related ...

The ATO's R&D Tax Incentive enables companies to receive 43.5% of eligible research and development expenditure.

Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange

by Myles Hume

November 18, 2020

Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority ...